Thrombosis, anticoagulation and outcomes in malignant superior vena cava syndrome

Roy Ratzon, Shlomit Tamir, Tal Friehmann, Nir Livneh, Elizabeth Dudnik, Alon Rozental, Orly Hamburger-Avnery, David Pereg, Estela Derazne, Baruch Brenner, Pia Raanani, Hugo ten Cate, Galia Spectre, Avi Leader*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

8 Citations (Web of Science)


Anticoagulation is often used in superior vena cava syndrome (SVCS) associated with cancer (i.e malignant SVCS), even without thrombosis, but its effect on outcomes has not been reported. We aimed to determine factors and outcomes associated with thrombosis and anticoagulation in malignant SVCS. Patients with malignant SVCS diagnosed on computerized tomography (CT) were retrospectively included, indexed at diagnosis and followed for 6 months using medical records. The cohort included 183 patients with malignant SVCS of which 153 (84%) were symptomatic. Thirty of the 127 patients (24%) with a reviewable baseline CT had thrombosis of the SVC or tributaries at diagnosis. Patients with baseline thrombosis more often had symptomatic SVCS (p

Original languageEnglish
Pages (from-to)121-128
Number of pages8
JournalJournal of Thrombosis and Thrombolysis
Issue number1
Publication statusPublished - Jan 2019


  • Superior vena cava syndrome
  • Malignancy
  • Thrombosis
  • Anticoagulation

Cite this